Cytokinetics +32% after Q4 earnings beat estimates, revenue soars


Cytokinetics (CYTK +31.9%) skyrockets higher after Q4 results beat estimates on the top and bottom line, with revenue growth of more than 1,000%.

Q4 EPS of $0.22 beat expectations of an $0.08 loss, while revenues rose 1,012% Y/Y to $24.3M vs. $19.1M analyst consensus estimate.

CYTK says it expects to announce results from BENEFIT-ALS in the next few months, and is preparing for potential next steps in the development program for tirasemtiv and the planned advancement of omecamtiv mecarbil into the final expansion phase of COSMIC-HF.

Comments (2)
  • Mic-Tee
    , contributor
    Comments (2) | Send Message
     
    Balance at high risk
    7 Feb 2014, 01:11 PM Reply Like
  • whosez
    , contributor
    Comments (122) | Send Message
     
    Long but still in total shock. In no way, shape, or form did I see anything like this coming. Wow.
    7 Feb 2014, 01:56 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs